Skip to main content

Advertisement

Log in

Platelet-activating factor and P-selectin activities in thrombotic and nonthrombotic Behçet’s patients

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to compare plasma Platelet-activating factor (PAF) and P-selectin (CD62P) activities in Behçet’s disease patients with and without thrombosis.

Methods

In this cross-sectional and descriptive study, 30 consecutive Behçet’s patients were included, 15 of them with venous thrombosis. All patients were also divided into two subgroups according to the presence or absence of clinical activity. Plasma PAF levels, basal and Ca++ ionophore (A23187)-induced leukocyte (cellular) PAF activities, and platelet-rich plasma ΔCD62P activity (the mean fluorescent density difference between CD62P phycoerythrin-positive and -negative stains) were evaluated.

Results

In the thrombotic group, plasma PAF (P=0.001), basal leukocyte PAF (P=0.017), induced leukocyte PAF (P=0.024), and ΔCD62P (P=0.023) levels were significantly higher than in the nonthrombotic group. In the whole group of Behçet’s patients, there was a positive correlation between plasma PAF and ΔCD62P levels (r=0.533, P=0.002). When we compared clinically active and inactive patients with respect to the above parameters, there was no significant difference, irrespective of thrombosis. Plasma PAF (P=0.001), basal leukocyte PAF (P=0.004), and ΔCD62P (P=0.038) levels were significantly higher in the presence of both clinical activity and thrombosis than of clinical activity alone.

Conclusion

Platelet-activating factor and CD62P may contribute to endothelial injury and thrombosis development in Behçet’s disease. These two parameters seem related to the presence of thrombosis rather than clinical activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341:1284–1291

    Google Scholar 

  2. Yazıcı H, Yurdakul S, Hamuryudan V (1999) Behçet’s syndrome. Curr Opin Rheum 11:53–57

    Article  CAS  PubMed  Google Scholar 

  3. Koç Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S et al (1992) Vascular involvement in Behçet’s disease. J Rheumatol 19:402–410

    CAS  PubMed  Google Scholar 

  4. Gül A (2001) Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 19 [Suppl 24]:S6–S12

  5. Braquet P, Shen TY, Touqui L, Vargaftig B (1987) Perspectives in platelet activating factor research. Phamacol Rev 39:97–145

    CAS  Google Scholar 

  6. Zimmerman GA, McIntyre TM, Prescott SM (1995) Production of platelet-activating factor by human vascular endothelial cells: evidence of a requirement for specific agonists and modulation by prostacyclin. Circulation 72:718–727

    Google Scholar 

  7. de Bruijne-Admiral LG, Modderman PW, Von dem Borne AEG, Sonnenberg A (1992) P-selectin mediates Ca2+-dependent adhesion of activated platelets to many different types of leukocytes: detection by flow cytometry. Blood 80:134–142

    PubMed  Google Scholar 

  8. International Study Group for Behcet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080

    PubMed  Google Scholar 

  9. Salari H (1986) Solid-phase extraction and reversed-phase high performance liquid chromatographic technique for isolation and estimation of platelet activating factor in plasma. J Chromatogr 382:89–98

    CAS  PubMed  Google Scholar 

  10. Shattil SJ, Cunningham M, Hoxie JA (1987) Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 70:307–315

    CAS  PubMed  Google Scholar 

  11. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ (1990) Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 75:128–138

    CAS  PubMed  Google Scholar 

  12. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM (2002) The platelet-activating factor system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 3 [Suppl 5]:S294–S301

  13. Lorant DE, Zimmerman GA, McIntyre TM, Prescott SM (1995) Platelet-activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion. Semin Cell Biol 6:295–303

    PubMed  Google Scholar 

  14. Lehr HA, Weyrich AS, Saetzier RK et al (1997) Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J Clin Invest 99:2358–2364

    CAS  PubMed  Google Scholar 

  15. Elstat MR, La Pinc TR, Cowley FS, McEver RP, McIntyre TM, Prescott SM, Zimmerman GA (1995) P-selectin regulates platelet-activating factor synthesis and phagocytosis by monocytes. J Immunol 155:2109–2122

    PubMed  Google Scholar 

  16. Tetta C, Bussolino F, Modena V et al (1990) Release of platelet activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 91:244–256

    CAS  PubMed  Google Scholar 

  17. Warren JS, Mandel DM, Johnson KJ, Ward PA (1989) Evidence for the role of platelet activating factor in immune complex vasculitis in the rat. J Clin Invest 83:669–678

    CAS  PubMed  Google Scholar 

  18. Haznedaroğlu Ş, Karaaslan Y, Büyükaşık Y, Koşar A, Özcebe Oİ, Haznedaroğlu IC, Kirazlı Ş, Dündar SV (2000) Selectin adhesion molecules in Behçet’s disease. Ann Rheum Dis 59:61–63

    PubMed  Google Scholar 

  19. Demopoulos CA, Andrikopoulos NK, Antonopoulou S (1994) A simple and precise method for the routine determination of platelet-activating factor in blood and urine. Lipids 29:305–309

    CAS  PubMed  Google Scholar 

  20. Shinozaki K, Kawasaki T, Kambayashi J, Sakon M, Shiba E, Uemura Y, Ou M, Iwamoto N, Mori T (1994) A new method of purification and sensitive bioassay of platelet-activating-factor (PAF) in human whole blood. Life Sci 54:429–439

    Article  CAS  PubMed  Google Scholar 

  21. Imaizumi T (1991) Intravascular release of a platelet-activating factor-like lipid (PAF-LL) induced by cigarette smoking. Lipids 26:1269–1273

    CAS  PubMed  Google Scholar 

  22. Imaizumi T, Satoh K, Yoshida H, Kawamura Y, Hiramoto M, Koyanagi M, Takamatsu S, Takamatsu M (1990) Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from healthy habitual cigarette smokers. Heart Vessels 5:81–86

    CAS  PubMed  Google Scholar 

  23. Miyaura S, Eguchi H, Johnston JM (1992) Effect of a cigarette smoke extract on the metabolism of the proinflammatory autocoid, platelet-activating factor. Circ Res 70:341–347

    CAS  PubMed  Google Scholar 

  24. Sturm MJ, Strophair JM, Kendrew PJ, Vandongen R, Beilin LJ, Taylor RR (1989) Whole blood aggregation and plasma lyso-PAF related to smoking and atherosclerosis. Clin Exp Pharmacol Physiol 16:597–605

    CAS  PubMed  Google Scholar 

  25. Bithell TC (1993) The physiology of primary hemostasis. In: Lee GR, Bithell TC, Foerster J, Atkens JW, Lukens JN (eds) Wintrobe’s clinical hematology, 9th edn. Lea and Febiger, Philadelphia, pp 549–550

  26. Hayashi J, Hiromura K, Koizumi R, Shimizu Y, Maezawa A, Nojima Y, Naruse T (2001) Platelet-activating factor antagonist, SM-12502, attenuates experimental glomerular thrombosis in rats. Nephron 87:274–278

    Article  CAS  PubMed  Google Scholar 

  27. Downing LJ, Wakefield TW, Strieter RM et al (1997) Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg 25:816–827

    CAS  PubMed  Google Scholar 

  28. Myers DD Jr, Henke PK, Wrobleski SK et al (2002) P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model. J Vasc Surg 36:928–938

    Article  PubMed  Google Scholar 

  29. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yakota M (2000) Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 150:209–216

    CAS  PubMed  Google Scholar 

  30. Taylor RR, Sturm M, Kendrew PJ, Vandongen R, Beilin LJ (1989) Plasma levels of the lyso-derivative of platelet-activating factor are related to age. Clin Sci (Colch) 76:195–198

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Ercan Tunc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tunc, S.E., Aksu, K., Keser, G. et al. Platelet-activating factor and P-selectin activities in thrombotic and nonthrombotic Behçet’s patients. Rheumatol Int 25, 326–331 (2005). https://doi.org/10.1007/s00296-004-0450-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-004-0450-4

Keywords

Navigation